The natural history of preclinical diastolic dysfunction: a population-based study
Mark W Vogel1, Joshua P Slusser, David O Hodge
1Department of Medicine, Division of Cardiovascular Diseases, and the Division of Biostatistics, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Insights
Progression from preclinical diastolic dysfunction (stage B) to symptomatic heart failure (stage C) occurred in 11.6% of patients over 3 years. Renal dysfunction was a key independent risk factor for this progression.
Area of Science:
- Cardiology
- Nephrology
- Public Health
Background:
- Preclinical diastolic dysfunction (PDD) is defined as left ventricular diastolic dysfunction without heart failure (HF) or with normal systolic function.
- PDD is classified as stage B HF, while symptomatic HF is stage C.
- Identifying progression risk factors from stage B to stage C HF is crucial for early intervention.
Purpose of the Study:
- To determine risk factors for progression from stage B (preclinical) to stage C (symptomatic) heart failure.
- To investigate the association of renal dysfunction with HF progression in patients with PDD.
Main Methods:
- Population-based study using the Rochester Epidemiology Project.
- Identified 388 patients with grade 2-4 diastolic dysfunction and ejection fraction ≥50% between 2004-2005.
- Excluded patients with prior HF, atrial fibrillation, or severe valvular regurgitation.
Main Results:
- Over 3 years, 11.6% of patients progressed to symptomatic HF (stage C).
- Independent risk factors for HF progression included age, renal dysfunction, and elevated right ventricular systolic pressure.
- Renal insufficiency (eGFR <60 mL/min) was present in 34% of the cohort.
Conclusions:
- A moderate progression from stage B to stage C heart failure was observed over 3 years.
- Renal dysfunction is an independent predictor of HF progression in patients with PDD.
- Findings highlight the importance of renal health in managing diastolic dysfunction.
Background:
Preclinical diastolic dysfunction (PDD) has been broadly defined as subjects with left ventricular diastolic dysfunction, without the diagnosis of congestive heart failure (HF) and with normal systolic function. Our objective was to determine the risk factors associated with the progression from PDD (stage B) HF to symptomatic (stage C) HF.
Methods And Results:
Using the resources of the Rochester Epidemiology Project, all residents of Olmsted County, MN, who underwent echocardiography between January 1, 2004, and December 31, 2005, and had grade 2-4 diastolic dysfunction and ejection fraction ≥50% were identified. Patients with a diagnosis of HF before or within 30 days of the echocardiogram were excluded. Patients were also excluded if they had a diagnosis of atrial fibrillation or severe mitral or aortic valve regurgitation at the time of the echocardiogram. A total of 388 patients met the inclusion criteria. The mean age of the cohort was 67±12 years, with a female (57%) predominance. Prevalence of renal insufficiency (estimated glomerular filtration rate <60 mL/min per 1.73 m(2)) was 34%. The 3-year cumulative probabilities of development of (stage C) HF, development of atrial fibrillation, cardiac hospitalization, and mortality were 11.6%, 14.5%, 17.7%, and 10.1% respectively. In multivariable Cox proportional hazard regression analysis, we determined that age, renal dysfunction, and right ventricular systolic pressure were independently associated with the development of HF.
Conclusions:
This population-based study demonstrated that in PDD (stage B) HF, there was a moderate degree of progression to symptomatic (stage C) HF over 3 years, and renal dysfunction was associated with this progression independent of age, sex, hypertension, coronary disease, and ejection fraction.
More Related Videos
04:48Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
Published on: November 28, 2018
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Related Concept Videos
Heart Failure II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Hypertension II: Pathophysiology
